BRPI0417117A - temozolomida cristalizada, processo de preparação de temozolomida cristalizada, composição farmacêutica, método de produção de medicamento contendo temozolomida e método de tratamento de uma condição médica para a qual a termozolomida é benéfica - Google Patents

temozolomida cristalizada, processo de preparação de temozolomida cristalizada, composição farmacêutica, método de produção de medicamento contendo temozolomida e método de tratamento de uma condição médica para a qual a termozolomida é benéfica

Info

Publication number
BRPI0417117A
BRPI0417117A BRPI0417117-9A BRPI0417117A BRPI0417117A BR PI0417117 A BRPI0417117 A BR PI0417117A BR PI0417117 A BRPI0417117 A BR PI0417117A BR PI0417117 A BRPI0417117 A BR PI0417117A
Authority
BR
Brazil
Prior art keywords
temozolomide
crystallized
beneficial
pharmaceutical composition
preparation process
Prior art date
Application number
BRPI0417117-9A
Other languages
English (en)
Inventor
Itai Adin
Carmen Iustain
Original Assignee
Chemagis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemagis Ltd filed Critical Chemagis Ltd
Publication of BRPI0417117A publication Critical patent/BRPI0417117A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"TEMOZOLOMIDA CRISTALIZADA, PROCESSO DE PREPARAçãO DE TEMOZOLOMIDA CRISTALIZADA, COMPOSIçãO FARMACêUTICA, MéTODO DE PRODUçãO DE MEDICAMENTO CONTENDO TEMOZOLOMIDA E MéTODO DE TRATAMENTO DE UMA CONDIçãO MéDICA PARA A QUAL A TEMOZOLOMIDA é BENéFICA". Prevê, novas formas cristalinas de Temozolomida, métodos de preparação das mesmas, medicamentos incluindo as novas formas cristalinas de Temozolomida, e usos das mesmas no tratamento de condições médicas.
BRPI0417117-9A 2003-12-30 2004-12-30 temozolomida cristalizada, processo de preparação de temozolomida cristalizada, composição farmacêutica, método de produção de medicamento contendo temozolomida e método de tratamento de uma condição médica para a qual a termozolomida é benéfica BRPI0417117A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53294403P 2003-12-30 2003-12-30
PCT/IL2004/001189 WO2005063757A2 (en) 2003-12-30 2004-12-30 Novel crystalline forms of temozolomide

Publications (1)

Publication Number Publication Date
BRPI0417117A true BRPI0417117A (pt) 2007-03-06

Family

ID=34738847

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417117-9A BRPI0417117A (pt) 2003-12-30 2004-12-30 temozolomida cristalizada, processo de preparação de temozolomida cristalizada, composição farmacêutica, método de produção de medicamento contendo temozolomida e método de tratamento de uma condição médica para a qual a termozolomida é benéfica

Country Status (5)

Country Link
US (2) US7615632B2 (pt)
EP (2) EP2275425A1 (pt)
BR (1) BRPI0417117A (pt)
CA (1) CA2552095A1 (pt)
WO (1) WO2005063757A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2552095A1 (en) 2003-12-30 2005-07-14 Chemagis Ltd. Novel crystalline forms of temozolomide
DE102006007309B4 (de) 2005-02-17 2012-11-29 Chemagis Ltd. Verbessertes Verfahren zur Herstellung von Temozolomid
WO2008111092A1 (en) * 2007-03-09 2008-09-18 Fresenius Kabi Oncology Limited Crystalline temozolomide monohydrate and process for preparation thereof
WO2011072240A1 (en) * 2009-12-10 2011-06-16 Cedars-Sinai Medical Center Drug delivery of temozolomide for systemic based treatment of cancer
US9623041B2 (en) 2010-12-30 2017-04-18 Cedars-Sinai Medical Center Polymalic acid-based nanobiopolymer compositions
CN102329319B (zh) * 2011-07-19 2014-01-15 江苏奥赛康药业股份有限公司 替莫唑胺的晶型、其制备方法及其药用组合物
WO2015062481A1 (zh) 2013-10-29 2015-05-07 天士力控股集团有限公司 替莫唑胺晶型及其制备方法
EP3613436B1 (en) 2018-12-13 2021-06-02 Orphelia Pharma Oral suspension of temozolomide
CN116655640A (zh) * 2023-05-31 2023-08-29 南通大学 替莫唑胺晶体及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418208A (en) * 1980-12-29 1983-11-29 E. R. Squibb & Sons, Inc. N-Substituted iminodiacetic acids
US5260291A (en) 1981-08-24 1993-11-09 Cancer Research Campaign Technology Limited Tetrazine derivatives
OA07174A (fr) * 1981-08-24 1984-04-30 May & Baker Ltd Nouvelles imidazotétrazionones, leur préparation et les médicaments qui les contiennent.
US4692327A (en) * 1984-09-06 1987-09-08 Fujimori Kogyo Co., Inc. Laminated film for packaging
US4805001A (en) * 1986-10-02 1989-02-14 Sharp Kabushiki Kaisha Magnification converting mechanism for a variable magnification copying apparatus
US4731053A (en) * 1986-12-23 1988-03-15 Merck & Co., Inc. Container device for separately storing and mixing two ingredients
US6858631B1 (en) 1999-11-29 2005-02-22 Merck & Co., Inc. Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl
US20040223951A1 (en) 2000-01-24 2004-11-11 Schering Corporation Combination therapy for cancer
US6346596B1 (en) * 2000-07-14 2002-02-12 Valspar Corporation Gas barrier polymer composition
CN101220033A (zh) 2001-01-18 2008-07-16 先灵公司 替莫唑胺和类似物的合成
WO2002057268A1 (en) 2001-01-18 2002-07-25 Schering Corporation Synthesis of temozolomide and analogs
US6874938B2 (en) * 2002-04-22 2005-04-05 S.C. Johnson Home Storage, Inc. Jacketed reclosable container
CA2517004A1 (en) * 2003-02-19 2004-09-02 Teva Pharmaceutical Industries Ltd. Methods of stabilizing azithromycin during storage by packaging in a gas impermeable container
CA2552095A1 (en) * 2003-12-30 2005-07-14 Chemagis Ltd. Novel crystalline forms of temozolomide
DE102006007309B4 (de) * 2005-02-17 2012-11-29 Chemagis Ltd. Verbessertes Verfahren zur Herstellung von Temozolomid

Also Published As

Publication number Publication date
US20050187206A1 (en) 2005-08-25
EP1706407A2 (en) 2006-10-04
EP2275425A1 (en) 2011-01-19
US7615632B2 (en) 2009-11-10
WO2005063757A3 (en) 2005-09-09
WO2005063757A2 (en) 2005-07-14
CA2552095A1 (en) 2005-07-14
US20100022609A1 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
IL226313A0 (en) A method for producing gamma-carboxylated human prothrombin, isolated prothrombin produced by such a method, a pharmaceutical preparation including it and its use as drugs and for the production of drugs for the treatment of blood coagulation
CY1115484T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπεια αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων, οπως νοσος alzheimer, διαβητης τυπου 2 και νοσος parkinson
BRPI0406592A (pt) Usos de n-desmetilclozapina, métodos para o tratamento de psicose, de distúrbios afetivos, de demência, de dor neuropática e de glaucoma e composição farmacêutica
IL158589A (en) Carboxylic acid substituted oxazole derivatives, process for their manufacture, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment and prophylaxis of diseases which are modulated by ppar-alpha and -gamma activators
DE50102490D1 (de) Verwendung von substituierten imidazo [1,2-a]pyridin-, -pyrimidin- und -pyrazin-3-yl-amin-derivaten zur herstellung von medikamenten zur nos-inhibierung
IL169954A (en) Tricyclo substituted amide compounds, process for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for the treatment of a condition where activation of gk is desirable
BRPI0210941B8 (pt) produto farmacêutico contendo combinações de oxazolidinonas substituídas, seu uso, seu processo de produção, e medicamento
MXPA05008617A (es) Usos de anticuerpos anti-receptor del factor de crecimiento semejante a la insulina i.
UA101393C2 (ru) КОМПОЗИЦИИ И ПРИМЕНЕНИЕ ПРОИЗВОДНЫХ ТРИАЗОЛА ДЛЯ ЛЕЧЕНИЯ β-АМИЛОИДОЗОВ И СИНУКЛЕИНОПАТИЙ
CY1108401T1 (el) Παραγωγα πυρρολοϊμιδαζολης, η παρασκευη τους, φαρμακευτικες συνθεσεις που τα περιεχουν και η χρηση τους ως νοοτροπικων παραγοντων
DE60328722D1 (de) Verfahren zur herstellung von tannat-tabletten, kapseln oder anderen festen dosierformen
BRPI0417117A (pt) temozolomida cristalizada, processo de preparação de temozolomida cristalizada, composição farmacêutica, método de produção de medicamento contendo temozolomida e método de tratamento de uma condição médica para a qual a termozolomida é benéfica
TW200505880A (en) Diarylcycloalkyl derivatives, process for their preparation and their use as pharmaceuticals
ATE526015T1 (de) Arzneimittel sowie deren herstellung und verwendung bei der behandlung von schmerzhaften neuropathien
EA200600854A1 (ru) Новые соли тиотропия, способ их получения, а также содержащие их лекарственные композиции
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
MX9304365A (es) Una forma de dosis osmotica para administrar tandospirona.
NZ594154A (en) Transdermal administration of buprenorphine for preoperative treatment of post operative pain
DE602004022284D1 (de) Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid-neurotoxizität und mikrogliosis
TW200505830A (en) Cycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals
DE602004016754D1 (de) Kombinationstherapie gegen krebserkrankungen mit azd2171 und zd1839
ATE353887T1 (de) Verfahren zur herstellung optisch reiner oder optisch angereicherter sulfoxidverbindungen einschliesslich amorphen esomeprazols und dessen salze
Schneider et al. The evil of the unknown-risk-benefit evaluation of new synthetic drugs in the 19th century
DE602006009848D1 (de) Die regeneration von neuronen des zentralen nervensystems stimulierende peptidsubstanz, darauf basierende pharmazeutische zusammensetzung und verfahren zu ihrer anwendung
BRPI0417797A (pt) soro sangüìneo biologicamente ativo, métodos para produzi-lo e seus usos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 8A E 9A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2259 DE 22/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 8A, 9A, 10A, 11A, 12A, 13A, 14A E 15A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.